Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct 31;27(12):111224.
doi: 10.1016/j.isci.2024.111224. eCollection 2024 Dec 20.

Primary tumor resection in de novo metastatic breast cancer from an oligometastatic perspective: A systematic review and meta-analysis

Chen Wu  1 , Xiang Li  1 , Shiyang Liu  1 , Litong Yao  1 , Tianyi He  1 , Yusong Wang  1 , Haoran Dong  1 , Shuyi Niu  1 , Mozhi Wang  1 , Yingying Xu  1
Affiliations

Primary tumor resection in de novo metastatic breast cancer from an oligometastatic perspective: A systematic review and meta-analysis

Chen Wu et al. iScience. .

Abstract

Whether patients with de novo metastatic breast cancer (de novo MBC) benefit from primary tumor resection (PTR) is controversial, and the efficacy of treatment of primary tumor in patients with oligometastases is uncertain. A comprehensive search was conducted for studies published from January 1, 2008 to January 1, 2024 that compared PTR with no PTR for de novo MBC that quantified the extent of metastasis. Ten studies and 83,559 patients with de novo MBC were included. A meta-analysis showed a significant improvement in overall survival after PTR compared with no PTR (hazard ratio [HR], 0.60; 95% confidence interval [CI], 0.53-0.67; p < 0.00001). Similar results were seen in patients with 1 metastatic organ, ≤2 metastatic organs, and ≤3 metastatic organs. Oligometastatic patients are expected to be a beneficial subgroup for PTR in patients with MBC, especially when metastasis occurs in only one organ.

Keywords: health sciences; internal medicine; medical specialty; medicine; oncology.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

None
Graphical abstract
Figure 1
Figure 1
Treatment options for breast cancer with different degrees of metastasis inferred from the metastatic function MBC, metastatic breast cancer; LMBC, locally metastatic breast cancer; OMBC, oligometastatic breast cancer; PMBC, polymetastatic breast cancer.
Figure 2
Figure 2
Study selection scheme
Figure 3
Figure 3
OS in limited extent of metastasis PTR, primary tumor resection.
Figure 4
Figure 4
OS in OMBC defined as limited metastatic sites (A) 1 metastatic site. (B) ≤2 metastatic sites. (C) ≤3 metastatic sites.
Figure 5
Figure 5
OS in OMBC defined as ≤3 metastases
See this image and copyright information in PMC

References

    1. Gennari R., Audisio R.A. Surgical removal of the breast primary for patients presenting with metastases - where to go? Cancer Treat Rev. 2009;35:391–396. doi: 10.1016/j.ctrv.2009.03.003. - DOI - PubMed
    1. Cardoso F., Paluch-Shimon S., Senkus E., Curigliano G., Aapro M.S., André F., Barrios C.H., Bergh J., Bhattacharyya G.S., Biganzoli L., et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) Ann. Oncol. 2020;31:1623–1649. doi: 10.1016/j.annonc.2020.09.010. - DOI - PMC - PubMed
    1. Liu D., Fang L. Current research on circular RNAs and their potential clinical implications in breast cancer. Cancer Biol. Med. 2021;18:635–648. doi: 10.20892/j.issn.2095-3941.2020.0275. - DOI - PMC - PubMed
    1. Kim S., Shin D., Min A., Kim M., Na D., Lee H.-B., Ryu H.S., Yang Y., Woo G.-U., Lee K.-H., et al. Genomic profile of metastatic breast cancer patient-derived xenografts established using percutaneous biopsy. J. Transl. Med. 2021;19:7. doi: 10.1186/s12967-020-02607-2. - DOI - PMC - PubMed
    1. Gradishar W.J., Moran M.S., Abraham J., Abramson V., Aft R., Agnese D., Allison K.H., Anderson B., Burstein H.J., Chew H., et al. NCCN Guidelines{textregistered} Insights: breast cancer, version 4.2023: featured updates to the NCCN guidelines. J. Natl. Compr. Cancer Netw. 2023;21:594–608. doi: 10.6004/jnccn.2023.0031. - DOI - PubMed

LinkOut - more resources